Octaplasma (Human Plasma Protein)

Human Plasma Protein, the active ingredient in Octaplasma, is a plasma-derived product presented as an intravenous solution for intravenous use. It provides a balanced mixture of clotting factors and plasma proteins to support hemostasis in patients with bleeding disorders, massive transfusion, liver disease, or undergoing major surgery.

GNH USA supplies Octaplasma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, and clinical facilities worldwide.

Octaplasma is used to replace deficient clotting factors in various bleeding disorders and surgical settings.

- Massive transfusion: restores clotting factor balance and reduces bleeding risk in patients receiving large-volume blood component therapy. - Liver disease–associated coagulopathy: supplies clotting factors to patients with impaired synthesis due to hepatic dysfunction. - Disseminated intravascular coagulation (DIC): provides plasma proteins to help re‑establish hemostasis during consumptive coagulopathy.

Octaplasma may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever - Chills - Headache - Nausea - Mild allergic rash - Transient hypertension

Serious or Rare Side Effects: - Anaphylactic reaction - Transfusion‑related acute lung injury (TRALI) - Severe hemolysis - Volume overload leading to pulmonary edema

When using Octaplasma, healthcare professionals should observe several precautionary measures to ensure patient safety.

- Verify patient identity and indication: confirm need for plasma protein replacement before administration. - Assess for prior transfusion reactions: review history of allergic or anaphylactic responses to plasma products. - Monitor coagulation parameters: check PT/INR, aPTT, fibrinogen levels before and after infusion. - Observe vital signs during infusion: watch for signs of hypotension, fever, or respiratory distress. - Use appropriate infusion rate: administer according to institutional protocols to minimize circulatory overload. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplasma can interact with certain medications and clinical conditions, requiring careful management.

Major Interactions (Avoid): - Concomitant use of high‑dose anticoagulants (e.g., warfarin, heparin) may exacerbate bleeding risk. - Administration with other plasma‑derived products can increase volume overload and immune sensitization.

Moderate Interactions (Monitor Closely): - Concurrent use of diuretics: may affect fluid balance during infusion. - Immunosuppressive therapy: monitor for altered immune response to plasma proteins. - Use with thrombolytic agents: observe for potential coagulation disturbances.